A5032050651- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- RNA modifications and cancer
- Cancer Research and Treatments
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Immune cells in cancer
- Cancer Genomics and Diagnostics
- Adenosine and Purinergic Signaling
- Cancer Cells and Metastasis
- Autophagy in Disease and Therapy
- Phagocytosis and Immune Regulation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Circular RNAs in diseases
- Cancer, Stress, Anesthesia, and Immune Response
- Glioma Diagnosis and Treatment
- Renal and related cancers
- CAR-T cell therapy research
- interferon and immune responses
- Hippo pathway signaling and YAP/TAZ
- Pancreatitis Pathology and Treatment
- Intestinal Malrotation and Obstruction Disorders
Tianjin Medical University Cancer Institute and Hospital
2021-2025
National Clinical Research
2021-2025
McMaster University
2025
Yahoo (United Kingdom)
2023
Tianjin Medical University
2021-2023
Children's Hospital of Zhejiang University
2023
Shandong University
2022
Union Hospital
2020
Huazhong University of Science and Technology
2020
State Key Laboratory of Information Engineering in Surveying Mapping and Remote Sensing
2020
Chemoresistance is the main reason for poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there an urgent need to screen out new targets and compounds reverse chemotherapeutic resistance.We established a bio-bank human PDAC organoid models, covering representative range tumor subtypes. We screened library 1304 FDA-approved identify candidates efficiently overcoming chemotherapy resistance. The effects were evaluated with CellTiter-Glo-3D assay, apoptosis assay in vivo...
Abstract Background Triple‐negative breast cancer (TNBC) is a highly heterogeneous and clinically aggressive disease. Accumulating evidence indicates that tertiary lymphoid structures (TLSs) tumor budding (TB) are significantly correlated with the outcomes of patients who have TNBC, but no integrated TLS‐TB profile has been established to predict their survival. The objective this study was investigate relationship between TLS/TB ratio clinical TNBC using artificial intelligence (AI)‐based...
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumour with limited treatment options. Here, we identified syndecan binding protein (SDCBP), also known as syntenin1, novel targetable factor in promoting PDAC progression. We explored therapeutic strategy for suppressing SDCBP expression.We used samples from patients PDAC, human organoid models, LSL-KrasG12D/+mice, LSL-Trp53R172H/+ and Pdx1-Cre (KPC) mouse PDX models. Immunostaining, colony formation assay, ethynyl-2-deoxyuridine...
The crosstalk between cancer stem cells (CSCs) and their niche is required for the maintenance of cell-like phenotypes CSCs. Here, we identified E26 transformation-specific homologous factor (EHF) as a key molecule in decreasing sensitivity pancreatic (PC) to CSCs' stimulus. We also explored therapeutic strategy restore expression EHF.We used LSL-KrasG12D/+mice, LSL-Trp53R172H/+ Pdx1-Cre (KPC) mouse model samples from patients with PC. Immunostaining, flow cytometry, sphere formation assays,...
Purpose: Chronic gastroesophageal reflux disease (GERD) causes the abnormal of acid and bile salts, which would induce Barrett's esophagus (BE) esophageal adenocarcinoma (EAC). EGFR, as one main components exosome, plays an important role in cancer progression. Here, we investigated acidic salts (ABS)-induced exosomal EGFR EAC cell proliferation. Methods: Electronic microscopic examination Western blot were used to identify exosomes. blot, siRNA transfection, enzyme-linked immunosorbent...
Background: Colon adenocarcinoma (COAD) is one of the most prevalent cancers worldwide and has become a leading cause cancer death. Although many potential biomarkers COAD have been screened with bioinformatics method, it necessary to explore novel markers for diagnosis appropriate individual treatments patients due high heterogeneity this disease. Epithelial-to-mesenchymal transition (EMT)-mediated tumor metastasis suggests poor prognosis cancers. Ferroptosis involved in development. EMT...
Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic ductal adenocarcinoma (PDAC). However, development of drug resistance limits its efficacy, and specific mechanisms remain largely unknown. RUNX1, a key transcription factor in hematopoiesis, also involved malignant progression PDAC, but was unclear chemoresistance PDAC.Comparative analysis performed to screen GEM-resistance related genes using our single-cell RNA sequencing(scRNA-seq) data two public RNA-sequencing...
<title>Abstract</title> Objective UBR2 (also referred to as n-recognin 2, the E3 component of ubiquitin protein ligase) targets proteins with unstable N-terminal residues for polyubiquitination and proteasome-mediated degradation. It was initially identified a crucial oncogene during embryonic development. Nevertheless, function in triple-negative breast cancer (TNBC) its non-ubiquitination role, particularly suppressing antitumor immune responses, remain elusive. Methods Utilizing bulk RNA...
Tumor recurrence and mortality rates remain challenging in cancer patients despite comprehensive treatment. Neoadjuvant chemotherapy immunotherapy aim to eliminate residual tumor cells, reducing the risk of recurrence. However, drug resistance during neoadjuvant therapy is a significant hurdle. Recent studies suggest correlation between RNA methylation regulators (RMRs) response therapy.
The objective of this study is to improve the efficacy CLDN18.2/CD3 bispecific T-cell engagers (BiTEs) as a promising immunotherapy against pancreatic ductal adenocarcinoma (PDAC).
Abstract Background: STING agonists have emerged as a promising strategy in tumor immunotherapy. However, their overall efficacy is constrained by several limiting factors. Studies indicate that chronic activation of the pathway can facilitate immune evasion through secretion pro-inflammatory Pancreatic ductal adenocarcinoma (PDAC), highly aggressive gastrointestinal malignancy, notably resistant to Thus, understanding role signaling shaping microenvironment PDAC crucial for evaluating its...
Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. CD8+ T cells, cancer stem cells (CSCs), and tumor budding (TB) have been significantly correlated with the outcome of patients PDAC, but correlations independently reported. In addition, no integrated immune-CSC-TB profile for predicting survival in PDAC has established. Methods: Multiplexed immunofluorescence artificial intelligence (AI)-based comprehensive analyses were used quantification spatial distribution...
Background: Neoadjuvant therapy remains controversial in treating resectable pancreatic ductal adenocarcinoma (PDAC) patients. This study aims to assess the impact of neoadjuvant on survival patients with PDAC according their clinical stage. Methods: Patients resected Stage I–III from 2010 2019 were identified surveillance, epidemiology, and end results database. A propensity score matching method was utilized within each stage reduce potential selection bias between who underwent...
Colon adenocarcinoma (COAD) is a prevalent malignant tumor globally, contributing significantly to cancer-related mortality. COAD guidelines label MSI (Microsatellite instability) and MSS stability) subtypes as global classification criteria treatment strategy selection for COAD. Various combination therapies involving PD-L1 inhibitors adjuvant therapy enhance anti-tumor efficacy.
Abstract Background PDAC is a highly malignant and immune-suppressive tumor, posing great challenges to therapy. Methods In this study, we utilized multi-center RNA sequencing non-negative matrix factorization clustering (NMF) identify group of metabolism-related genes that could effectively predict the immune status survival (both disease-free overall survival) pancreatic ductal adenocarcinoma (PDAC) patients. Subsequently, through integration single cell our center's prospective...
Background Pancreatic ductal adenocarcinoma (PDAC) is a type of malignant tumor with five-year survival rate less than 10%. Gemcitabine (GEM) the most commonly used drug for PDAC chemotherapy. However, vast majority patients develop resistance after GEM treatment. Methods We screened genes through bioinformatics analysis. immunohistochemistry to analyze 3-oxoacid CoA-transferase 1 (OXCT1) expression in tissues. The data were analyzed using Kaplan–Meier curve. levels related OXCT1 and NF-κB...
When running applications in IaaS (Infrastructure as a Service) cloud platforms like Amazon EC2, users can choose to purchase reserved instances instead of on-demand ones save cost. However, if there are few workload arrivals after instance reservations, it will cause waste cost due the idle instances. At present, EC2 has launched market, which resell their avoid wastes. for users, is difficult make optimal decisions on whether when they do not know arrival situation workloads future. This...
Introduction: Lung adenocarcinoma is a common cause of mortality in patients with cancer. Recent studies have indicated that copper-related cell death may not occur the same way as previously described. Long non-coding RNAs (lncRNAs) play key role occurrence and development tumors; however, relationship between cuproptosis lncRNAs tumorigenesis lung (LUAD) treatment has been well established. Our study aimed to construct model analyze prognosis using carcinogenesis-related lncRNA (CR)...